In a world where obesity is a common problem, slimming injections such as Unattics (Smaglotide), Vigobobi (Smaglotide) and Mongero (Tirazptide) have become popular thanks to their ability to help people lose weight significantly.
But there are other good news: recent studies show that these drugs, belonging to a group of GLP-1 receptor agonists, may reduce the risk of developing certain types of cancer, especially those related to obesity. This is not only because of weight loss, but also because of other effects such as reducing inflammation in the body and improving control of sugar levels.
Posts that are published on Israel Time blogs represent their writers only. Opinions, facts and any content shown in this post are the responsibility of the blogger and the time of Israel does not carry responsibility for them. In the event of a complaint, please contact us.